Intercell AG, the Austrian vaccine developer, made a restructuring and impairment charge in the 2010 fourth quarter of €182.8 million, mainly as the result of terminating a vaccine patch project in Phase 3 development.
Daiichi Sankyo Co Ltd has reached an agreement to acquire Plexxikon Inc of the US, which has a product for metastatic melanoma in Phase 3, along with a companion diagnostic. The Japanese company is offering $805 million for Plexxikon.
TiGenix NV of Belgium and Cellerix SA of Spain have agreed to merge creating what is expected to be the largest cell therapy and regenerative medicine company in Europe. It is the most significant corporate transaction in the field of regenerative medicine since the December 2010 alliance between Cephalon Inc and Mesoblast Ltd of Australia
4SC AG, which has a portfolio of products focused on autoimmune and cancer indications, has raised a gross €11.74 million in a private placement with institutional investors to finance its ongoing product development activities.
Intercell AG, the Austrian vaccine developer, is raising €33 million with a three-year convertible note issue which gives its institutional investors considerable leverage possibilities. The company increased the private placement to meet demand.
The Roche Group has ended a licensing deal with Transgene SA relating to a clinical-stage therapeutic vaccine. This is the third case in less than three weeks in which a large pharmaceutical company has apparently precipitously cancelled a deal with a smaller biopharmaceutical company.
Johnson & Johnson Inc has declared its €24.75 per-share offer for Crucell NV, the Dutch developer of therapeutic and prophylactic vaccines, unconditional. Crucell will now operate as a vaccine centre within J&J. The two companies announced completion of the merger on 22 February 2011.
Philogen SpA has withdrawn its proposed initial public offer of shares on the Milan Stock Exchange following the unexpected termination of a licensing and development contract by Bayer Schering Pharma AG, according to Philogen.
Sanofi-Aventis SA has won the agreement of Genzyme Corp’s management to acquire the US company for $74 per share in cash, plus special milestone payments if certain product goals are met. The offer is an increase from $69 per share.
E-Therapeutics Plc, which is a service company and a drug developer, is proposing to raise £17.6 million gross through a primary share offering arranged by Panmure Gordon, which is also overseeing a £3.4 million secondary offering of E-Therapeutics shares.